Skip to main content
SpringerLink
Log in
Book cover

NeuroIntensiv pp 551–571Cite as

Autoimmunerkrankungen

  • Chapter

  • 3723 Accesses

Zusammenfassung

Die Sarkoidose ist eine multisystemische granulomatöse Autoimmunerkrankung unbekannter Ätiologie. Beobachtet wird eine gehäufte Assoziation mit bestimmten HLA-Genen (HLA-B8, HLA-DR17). Aufgrund der Immunreaktionen in den Frühphasen der Erkrankung vermutet man, dass bei einer entsprechenden genetischen Disposition infektiöse und nichtinfektiöse antigene Umgebungsfaktoren in den Zielorganen zu Aktivierung und Expansion von T-Zellen, insbesondere TH1-Zellen, führt, die die Immunreaktion initiieren.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Zu 33.1

  1. ATS Board of Directors and by the ERS Executive Committee. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG). February 1999. Am J Respir Crit Care Med 1999; 160:736–755

    Google Scholar 

  2. Barnard J, Newman LS. Sarcoidosis: immunology, rheumatic involvement, and therapeutics. Curr Opin Rheumatol 2001; 13: 84–91

    PubMed  CAS  Google Scholar 

  3. Berger C, Sommer C, Meinck HM. Isolated sarcoid myopathy. Muscle Nerve 2002; 26:553–556

    PubMed  Google Scholar 

  4. Bolat S, Berding G, Dengler R, StangelM, Trebst C. Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. J Neurol Sci 2009; 287:257–259

    PubMed  CAS  Google Scholar 

  5. Bunting PS, Szalai JP, Katic M. Diagnostic aspects of angiotensin converting enzyme in pulmonary sarcoidosis. Clin Biochem. 1987; 20: 213–219

    PubMed  CAS  Google Scholar 

  6. Christoforidis GA, Spickler EM, Recio MV, Mehta BM. MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment. AJNR Am J Neuroradiol 1999; 20: 655–669

    PubMed  CAS  Google Scholar 

  7. Hayat GR, Walton TP, Smith KR Jr, Martin DS, Manepalli AN. Solitary intramedullary neurosarcoidosis: role of MRI in early detection. J Neuroimaging 2001; 11: 66–70

    PubMed  CAS  Google Scholar 

  8. Hershcovici T, Mekhmandorov S, Beigel Y, Hardoff R. The value of Ga-67 scintigraphy in sarcoid myopathy. Clin Nucl Med. 2001; 26: 540–542

    PubMed  CAS  Google Scholar 

  9. Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical dilemma. Lancet Neurol. 2004; 3: 397–407

    PubMed  Google Scholar 

  10. Hoitsma E, Drent M, Sharma OP. A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century. Curr Opin Pulm Med 2010; 16:472–479

    PubMed  Google Scholar 

  11. Kramers C, Deinum J. Increased serum activity of angiotensinconverting enzyme (ACE): indication of sarcoidosis? A ‘Bayesian’ approach] Ned Tijdschr Geneeskd 2003; 147: 473–476

    PubMed  CAS  Google Scholar 

  12. Leclerc S, Myers RP, Moussalli J, Herson S, Poynard T, Benveniste O. Sarcoidosis and interferon therapy: report of five cases and review of the literature. Eur J Intern Med 2003; 14: 237–243

    PubMed  CAS  Google Scholar 

  13. Nowak DA, Widenka DC. Neurosarcoidosis: a review of its intracranial manifestation. J Neurol 2001; 248: 363–372

    PubMed  CAS  Google Scholar 

  14. Reske D, Petereit HF, Heiss WD. Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system – value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis. Acta Neurol Scand 2005; 112: 207–213

    PubMed  CAS  Google Scholar 

  15. Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest. 2003; 124: 2028–2031

    PubMed  Google Scholar 

  16. Sohn HS, Kim EN, Park JM, Chung YA. Muscular sarcoidosis: Ga- 67 scintigraphy and magnetic resonance imaging. Clin Nucl Med 2001; 26: 29–32

    PubMed  CAS  Google Scholar 

  17. Ulbricht KU, Stoll M, Bierwirth J, Witte T, Schmidt RE. Successful tumor necrosis factor alpha blockade treatment in therapyresistant sarcoidosis. Arthritis Rheum 2003; 48: 3542–3354

    PubMed  Google Scholar 

  18. Walter MC, Lochmuller H, Schlotter-Weigel B, Meindl T, Muller-Felber W. Successful treatment of muscle sarcoidosis with thalidomide. Acta Myol 2003; 22: 22–25

    PubMed  CAS  Google Scholar 

  19. Woitalla D, Henkes H, Felber S, Weber W, Janisch W, Kuhne D. Clinical aspects and diagnostic imaging in sarcoidosis of the nervous system. Radiologe 2000; 40: 1064–1076

    PubMed  CAS  Google Scholar 

  20. Zettl UK, Lehmitz R, Mix E. Klinische Liquordiagnostik. de Gruyter 2003, Berlin, New York

    Google Scholar 

Zu 33.2

  1. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus. Arthritis Rheum 1999; 42:599–608

    Google Scholar 

  2. Berlit P. Neuropsychiatric disease in collagen vascular diseases and vasculitis. J Neurol 2007; 254:II87–89

    PubMed  Google Scholar 

  3. Berlit P. Diagnosis and treatment of cerebral vasculitis. Therapeutic Advances in Neurological Disorders 2010; 3:29–42

    PubMed  Google Scholar 

  4. Carson KR, Evens AM, Richey EA, Habermann TM , Focosi D, Seymour JF , Laubach J , Bawn SD , Gordon LI, Winter JN, Furman RR , Vose JM , Zelenetz AD , Mamtani R , Raisch DW, Dorshimer GW , Rosen ST , Muro K , Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834–4840

    PubMed  CAS  Google Scholar 

  5. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343:1156–1162

    PubMed  CAS  Google Scholar 

  6. Hanly JG. ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus 2004; 13:861–864

    PubMed  CAS  Google Scholar 

  7. Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 2006;54:2515–2522

    PubMed  CAS  Google Scholar 

  8. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135:248–257

    PubMed  CAS  Google Scholar 

  9. Krämer M, Berlit P (2011) Systemic, secondary and infectious causes for cerebral vasculitis: clinical experience with 16 new European cases. Rheumatol Int, in press

    Google Scholar 

  10. Mok CC, Ho CT, Chan KW, Lau CS, Wong RW. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002; 46:1003–1013

    PubMed  CAS  Google Scholar 

  11. Morton SJ, Powell RJ. Management of systemic lupus erythematosus (SLE). Clin Exp Allergy 2001; 31:686–693

    PubMed  CAS  Google Scholar 

  12. Mosca M, Ruiz-Irastorza G, Khamashta MA, Hughes GR. Treatment of systemic lupus erythematosus. Int Immunopharmacol 2001; 1:1065–1075

    PubMed  CAS  Google Scholar 

  13. Ortmann RA, Klippel JH. Update on cyclophosphamide for systemic lupus erythematosus. Rheum Dis Clin North Am 2000; 26:363–375, vii

    PubMed  CAS  Google Scholar 

  14. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet 2001; 357:1027–1032

    PubMed  CAS  Google Scholar 

  15. Sibbitt WL Jr., Sibbitt RR, Brooks WM. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999; 42:2026–2038

    PubMed  Google Scholar 

  16. Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001; 10:154–161

    PubMed  CAS  Google Scholar 

Zu 33.3

  1. Apak RA, Anlar B, Saatci I. A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment. Brain Dev 1999; 21:279–282

    PubMed  CAS  Google Scholar 

  2. Bizzi A, Ulug AM, Crawford TO, Passe T, Bugiani M, Bryan RN, Barker PB. Quantitative proton MR spectroscopic imaging in acute disseminated encephalomyelitis. AJNR Am J Neuroradiol 2001; 22:1125–1130

    PubMed  CAS  Google Scholar 

  3. Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000; 123 Pt 12:2407–2422

    PubMed  Google Scholar 

  4. Finsterer J, Grass R, Stollberger C, Mamoli B. Immunoglobulins in acute, parainfectious, disseminated encephalo-myelitis. Clin Neuropharmacol 1998; 21:258–261

    PubMed  CAS  Google Scholar 

  5. Gupte G, Stonehouse M, Wassmer E, Coad NA, Whitehouse WP. Acute disseminated encephalomyelitis: a review of 18 cases in childhood. J Paediatr Child Health 2003; 39:336–342

    PubMed  CAS  Google Scholar 

  6. Haase CG, Faustmann PM, Diener H. Idiopathic inflammatory demyelinating diseases of the central nervous system: differentiating between acute disseminated encephalomyelitis and malignant multiple sclerosis. J Clin Neurosci 1999; 6:221–226

    PubMed  Google Scholar 

  7. Hahn CD, Miles BS, MacGregor DL, Blaser SI, Banwell BL, Hetherington CR. Neurocognitive outcome after acute disseminated encephalomyelitis. Pediatr Neurol 2003; 29:117–123

    PubMed  Google Scholar 

  8. Hart MN, Earle KM. Haemorrhagic and perivenous encephalitis: a clinical-pathological review of 38 cases. J Neurol Neurosurg Psychiatry 1975; 38:585–591

    PubMed  CAS  Google Scholar 

  9. Hurst EW. Acute haemorrhagic leuco-encephalitis, a previuosly undefined entity. Medical Journal of Australia 1941; 2:1–6

    Google Scholar 

  10. Inglese M, Salvi F, Iannucci G, Mancardi GL, Mascalchi M, Filippi M. Magnetization transfer and diffusion tensor MR imaging of acute disseminated encephalomyelitis. AJNR Am J Neuroradiol 2002; 23: 267–272

    PubMed  Google Scholar 

  11. Ichiyama T, Shoji H, Kato M. Cerebrospinal fluid levels of cytokines and soluble tumour necrosis factor receptor in acute disseminated encephalomyelitis. Eur J Pediatr 2002; 161:133–137

    PubMed  CAS  Google Scholar 

  12. Krupp LB, Banwell B, Tenembaum S, for the International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related childhood disorders. Neurology 2007; 68 (Suppl 2):S7–S12

    PubMed  Google Scholar 

  13. Kanter DS, Horensky D, Sperling RA, Kaplan JD, Malachowski ME, Churchill WH Jr. Plasmapheresis in fulminant acute disseminated encephalomyelitis. Neurology 1995;45:824–827

    PubMed  CAS  Google Scholar 

  14. Markus R, Brew BJ, Turner J, Pell M. Successful outcome with aggressive treatment of acute haemorrhagic leukoencephalitis. J Neurol Neurosurg Psychiatry 1997 Oct; 63(4):551

    PubMed  CAS  Google Scholar 

  15. Niedermayer I, Deinzer M, Moringlane JR, Feiden W. Neuropathological and neuroradiological aspects of acute disseminated encephalomyelitis (ADEM). Radiologe 2000; 40:1030–1035

    PubMed  CAS  Google Scholar 

  16. Pasternak JF, De Vivo DC, Prensky AL. Steroid-responsive encephalomyelitis in childhood. Neurology 1980; 30:481–486

    PubMed  CAS  Google Scholar 

  17. Pfausler B, Engelhardt K, Kampfl A, Spiss H, Taferner E, Schmutzhard E. Post-infectious central and peripheral nervous system diseases complicating Mycoplasma pneumoniae infection. Report of three cases and review of the literature. Eur J Neurol 2002; 9:93–96

    PubMed  CAS  Google Scholar 

  18. Poser S, Luer W, Bruhn H, Frahm J, Bruck Y, Felgenhauer K. Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand 1992; 86:579–585

    PubMed  CAS  Google Scholar 

  19. Ravaglia S, Corso A, Piccolo G, Lozza A, Alfonsi E, Mangiacavalli S, Varettoni M, Zappasodi P, Moglia A, Lazzarino M, Costa A. Severe steroid-resistant postinfectious encephalomyelitis: general features and effects of IVIg. J Neurol 2007; 254:1518–1523

    PubMed  CAS  Google Scholar 

  20. Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B. Acute disseminated encephalomyelitis: a followup study of 40 adult patients. Neurology 2001; 56:1313–1318

    PubMed  CAS  Google Scholar 

  21. Schwarz S, Knauth M, Mohr A, Wildemann B, Sommer C, Storch-Hagenlocher B. Acute disseminated encephalomyelitis (ADEM) Nervenarzt 2001; 72:241–254

    PubMed  CAS  Google Scholar 

  22. Singh S, Alexander M, Korah IP. Acute disseminated encephalomyelitis: MR imaging features. AJR Am J Roentgenol 1999; 173:1101–1107

    PubMed  CAS  Google Scholar 

  23. Sonneville R, Klein IF, Wolff M. Update on investigation and management of postinfectious encephalitis. Current Opinion in Neurology 2010; 23:300–304

    PubMed  Google Scholar 

  24. Sugita K, Suzuki N, Shimizu N, Takanashi J, Ishii M, Niimi N. Involvement of cytokines in N-methyl-N’-nitro-Nnitrosoguanidine- induced plasminogen activator activity in acute disseminated encephalomyelitis and multiple sclerosis lymphocytes. Eur Neurol 1993; 33:358–362

    PubMed  CAS  Google Scholar 

  25. Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 2002; 59:1224–1231

    PubMed  Google Scholar 

  26. Tenembaum S, Chitnis T, Ness J, Hahn JS for the International Pediatric MS Study Group. Acute disseminated encephalomyelitis. Neurology 2007; 68(Suppl 2):S23–S36

    PubMed  Google Scholar 

  27. Van Der Knaap MS, Valk J. Magnetic resonance of myelin, myelination, and myelin disorders, 2nd ed. Springer 1995, Berlin, Heidelberg, New York

    Google Scholar 

  28. Zettl UK, Lehmitz R, Mix E. Klinische Liquordiagnostik. de Gruyter 2003, Berlin, New York

    Google Scholar 

Zu 33.4

  1. Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behcet’s disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain 1999; 122:2171–2182

    PubMed  Google Scholar 

  2. Bartels E. Farbduplexsonographie der hirnversorgenden Gefäße. Schattauer 1999, Stuttgart, New York

    Google Scholar 

  3. Berlit P. The spectrum of vasculopathies in the differential diagnosis of vasculitis. Sem Neurol 1994; 14:370–379

    CAS  Google Scholar 

  4. Berlit P, Steinbrecher A. Zerebrale Vaskulitis. Fortschr Neurol Psych 2002; 70:663–677

    CAS  Google Scholar 

  5. Bartels E. Farbduplexsonographie der hirnversorgenden Gefäße. Schattauer 1999, Stuttgart, New York

    Google Scholar 

  6. Calabrese LH, Gragg LA, Furlan AJ Benign angiopathy. A distinct subset of angiographically defined primary angiitis of the CNS. J Rheumatol 1993; 20:2046–2050

    PubMed  CAS  Google Scholar 

  7. Calabrese LH, Duna GF, Lie JT. Vasculitis in the central nervous system. Arthritis Rheum 1997; 40:1189–1201

    PubMed  CAS  Google Scholar 

  8. de Groot K, Muhler M, Reinhold-Keller E, Paulsen J, Gross WL. Induction of remission in Wegener’s granulomatosis with low dose methotrexate. J Rheumatol 1998; 25:492–495

    PubMed  Google Scholar 

  9. de Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Nolle B, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener’s granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996; 39:2052–2061

    PubMed  Google Scholar 

  10. de Groot K, Schmidt DK, Arlt AC, Gross WL, Reinhold-Keller E. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol 2001; 58:1215–1221

    PubMed  Google Scholar 

  11. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98:76–85

    PubMed  CAS  Google Scholar 

  12. Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P. Long-term follow up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44:666–675

    PubMed  CAS  Google Scholar 

  13. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 1997; 40:2187–2198

    PubMed  CAS  Google Scholar 

  14. Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 1995; 74:238–253

    CAS  Google Scholar 

  15. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, Thibult N, Casassus P. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75:17–28

    CAS  Google Scholar 

  16. Goldberg JW. Primary angiitis of the central nervous system. In: Rolak LA, Harati Y (eds) Neuroimmunology for the Clinician. Butterworth-Heinemann 1997, Boston, pp 177–186

    Google Scholar 

  17. Goodwin J. Temporal arteriitis. In: Gilman S (editor in chief ) Neurobase, 4th 2000 ed. Ann Arbor Publishing 2000

    Google Scholar 

  18. Guillevin L, Lhote F, Sauvaget F, Deblois P, Rossi F, Levallois D, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994; 53:334–337

    PubMed  CAS  Google Scholar 

  19. Haubitz M, Schellong S, Gobel U, Schurek HJ, Schaumann D, Koch KM, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998; 41:1835–1844

    PubMed  CAS  Google Scholar 

  20. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, Salvarani C, Xu W, Visvanathan S, Rahman MU (Infliximab-GCA Study Group). Ann Intern Med 2007; 146:621–630

    PubMed  Google Scholar 

  21. Holle JU, Gross WL. Neurological involvement in Wegener’s granulomatosis. Curr Opin Rheumatol 2011; 23:7–11

    PubMed  Google Scholar 

  22. Irani DN. Neurologic complications of the hepatitis virus. In: Gilman S (editor in chief ) Neurobase, 4th ed. Ann Arbor Publishing 2000

    Google Scholar 

  23. Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Behcet’s syndrome. Brain 1999; 122:2183–2194

    PubMed  Google Scholar 

  24. Kraemer M, Berlit P. Primary central nervous system vasculitis: clinical experiences with 21 new European cases. Rheumatol Int 2011; 31:463–472

    PubMed  Google Scholar 

  25. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener’s granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42:2666–2673

    PubMed  CAS  Google Scholar 

  26. McRae D, Buchanan G. Long-term sulfamethoxazoletrimethoprim in Wegener’s granulomatosis. Arch Otolaryngol Head Neck Surg 1993; 119:103–105

    PubMed  CAS  Google Scholar 

  27. Moore PM. Diagnosis and management of isolated angiitis of the central nervous system. Neurology 1989; 39:167–173

    PubMed  CAS  Google Scholar 

  28. Moore PM, Richardson B. Neurology of the vasculitides and connective tissue diseases. J Neurol Neurosurg Psychiat 1998; 65:10–22

    PubMed  CAS  Google Scholar 

  29. Murphy JM, Gomez-Anson B, Gillard JH. Wegener Granulomatosis: MR Imaging findings in brain and meninges. Radiology 1999; 213:794–799

    PubMed  CAS  Google Scholar 

  30. Newman GC. CNS Vasculitis. Clinical neuroimmunology, Education Syllabus, AAN 1998, pp 2FC.005-143-2FC.005-174

    Google Scholar 

  31. Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE. Neurological involvement in Wegener’s granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 1993; 33:4–9

    PubMed  CAS  Google Scholar 

  32. Pomper MG, Miller TJ, Stone JH. CNS vasculitis in autoimmune disease: MR imaging findings and correlation with angiography. AJNR 1999; 20:75–85

    PubMed  CAS  Google Scholar 

  33. Provenzale JM, Allen NB. Wegener granulomatosis: CT and MR findings. ANJR 1996; 17:785–792

    CAS  Google Scholar 

  34. Reinhold-Keller E, De Groot K, Rudert H, Nolle B, Heller M, Gross WL. Response to trimethoprim/sulfamethoxazole in Wegener’s granulomatosis depends on the phase of disease. QJM 1996; 89:15–23

    PubMed  CAS  Google Scholar 

  35. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet’s disease. N Engl J Med 1999; 341:1284–1291

    PubMed  CAS  Google Scholar 

  36. Salvarani C, Brown RD Jr, Calamia KT, Christianson TJ, Weigand SD, Miller DV, Giannini C, Meschia JF, Huston J 3rd, Hunder GG. Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol 2007; 62:442–451

    PubMed  Google Scholar 

  37. Schmidley JW. Central nervous system angiitis. Butterworth- Heinemann 2000, Boston

    Google Scholar 

  38. Schmidt WA, Kraft HE, Vorpahl K, Lutz V, Gromnica-Ihle EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997; 337:1336–1342

    PubMed  CAS  Google Scholar 

  39. Siva A, Fresko II. Behcet’s Disease. Curr Treat Options Neurol 2000; 2:435–448

    PubMed  Google Scholar 

  40. Siva A. Vasculitis of the nervous system. J Neurol 2001; 248:451–468

    PubMed  CAS  Google Scholar 

  41. Specks U, Moder KG, McDonald TJ. Meningeal involvement in Wegener granulomatosis. Mayo Clin Proc 2000; 75:856–859

    PubMed  CAS  Google Scholar 

  42. Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001; 19:495–501

    PubMed  CAS  Google Scholar 

  43. Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335:16–20

    PubMed  CAS  Google Scholar 

  44. Stone JH, Tun W, Hellman DB. Treatment of non-life threatening Wegener’s granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 1999; 26:1134–1139

    PubMed  CAS  Google Scholar 

  45. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124:477–484

    PubMed  CAS  Google Scholar 

  46. Valeriano-Marcet J, Spiera H. Treatment of Wegener’s granulomatosis with sulfamethoxazole-trimethoprim. Arch Intern Med 1991; 151:1649–1652

    PubMed  CAS  Google Scholar 

  47. Wechsler B, Dell’Isola B, Vidailhet M, Dormont D, Piette JC, Bletry O, Godeau P. MRI in 31 patients with Behçet’s disease and neurological involvement. Prospective study with clinical correlation. J. Neurol Neurosurg Psychiat 1993; 56:793–798

    CAS  Google Scholar 

  48. Woolfenden AR, Tong DC, Marks MP, et al. (1998) Angiographically defined primary angiitis of the CNS: Is it really benign? Neurology 51:183–188

    PubMed  CAS  Google Scholar 

  49. Yazici H, Yurdakul S, Hamuryudan V. Behcet disease. Curr Opin Rheumatol 2001; 13:18–22

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurologische Klinik, Friedrich-Alexander- Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen

    Prof. Dr. Stefan Schwab

  2. Benediktuskrankenhaus, Neurologische Klinik und Geriatrie Johannes Wesling Klinikum Minden, Hans-Nolte-Str. 1, 32429, Minden

    Prof. Dr. Peter Schellinger

  3. Klinik für Anästhesiologie, Klinikum der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55131, Mainz

    Prof. Dr. Christian Werner

  4. Neurochirurgische Klinik, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg

    Prof. Dr. Andreas Unterberg & Prof. Dr. Dr. Werner Hacke

Authors
  1. Prof. Dr. Stefan Schwab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. Peter Schellinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. Christian Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. Dr. Andreas Unterberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Prof. Dr. Dr. Werner Hacke
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neurologische Klinik, Friedrich-Alexander-Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen

    Stefan Schwab

  2. Benediktuskrankenhaus, Neurologische Klinik und Geriatrie Johannes Wesling Klinikum Minden, Hans-Nolte-Str. 1, 32429, Minden

    Peter Schellinger

  3. Klinik für Anästhesiologie, Klinikum der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55131, Mainz

    Christian Werner

  4. Neurochirurgische Klinik, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg

    Andreas Unterberg  & Werner Hacke  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schwab, S., Schellinger, P., Werner, C., Unterberg, A., Hacke, W. (2012). Autoimmunerkrankungen. In: Schwab, S., Schellinger, P., Werner, C., Unterberg, A., Hacke, W. (eds) NeuroIntensiv. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-16911-3_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-16911-3_33

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-16910-6

  • Online ISBN: 978-3-642-16911-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation